Communiqués AstraZeneca PLC NYSE

Actions

AZN

US0463531089

Produits pharmaceutiques

Marché Fermé - NYSE Autres places de cotation 22:00:02 27/07/2026			Varia. 5j.	Varia. 1 janv.
169,64 ^USD	+0,22 %		+0,21 %	+84,53 %

27/07	Les actions européennes stables, la faiblesse de la technologie compense l'optimisme lié aux tensions USA-Iran	RE
27/07	Les bourses bondissent alors que l'accalmie entre les États-Unis et l'Iran fait chuter les cours du pétrole	AN

Communiqués

27/07	Beyond De-risking: How European Companies Can Develop New Technologies In China	AQ
27/07	Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers	BU
27/07	AstraZeneca results: H1 and Q2 2026	BU
27/07	Astrazeneca: Q2 Earnings Snapshot	AQ
27/07	AstraZeneca : Update on Phase III trial of Ultomiris in adults and adolescents with thrombotic microangiopathy after haematopoietic stem cell transplant	PU
27/07	AstraZeneca : Update on Phase III trial of Ultomiris in adults and adolescents with thrombotic microangiopathy after haematopoietic stem cell transplant	PU
27/07	Half-year Financial Report	AQ
24/07	AstraZeneca : Enhertu plus pertuzumab recommended for approval in the EU by CHMP as 1st-line treatment for patients with HER2-positive metastatic breast cancer	PU
24/07	AstraZeneca : Trixeo recommended for approval in the EU by CHMP for the maintenance treatment of asthma	PU
15/07	Dizal Announces Global Exclusive License Agreement with AstraZeneca for Zegfrovy	AQ
14/07	AstraZeneca : enters exclusive global license agreement for novel oral EGFR inhibitor Zegfrovy for lung cancer with Dizal Pharmaceutical	PU
29/06	AstraZeneca : Enhertu approved in EU for HER2+ solid tumours	PU
29/06	AstraZeneca : Enhertu approved in the EU as first tumour agnostic HER2-directed therapy and antibody drug conjugate for patients with previously treated HER2-positive metastatic solid tumours	PU
29/06	AstraZeneca : Datroway recommended for approval in EU for TNBC	PU
28/06	AstraZeneca : Efzimfotase alfa demonstrated improvements in bone health in treatment-naïve paediatric patients with hypophosphatasia achieving median difference of 1.67 vs placebo in RGI-C Score at week 25 in MULBERRY Phase III trial	PU
26/06	AstraZeneca : Datroway recommended for approval in the EU by CHMP as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy	PU
24/06	AstraZeneca and YMCA of the USA Announce Landmark Partnership Aimed to Address Gaps in Cancer Care	BU
15/06	AstraZeneca : Ultomiris granted Priority Review in the US as treatment for adults with immunoglobulin A nephropathy	PU
15/06	AstraZeneca : Truqap approved in US for prostate cancer	PU
13/06	TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer	BU
12/06	AstraZeneca : Truqap combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer	PU
08/06	AstraZeneca : Elecoglipron, an oral small molecule GLP-1 RA, moves to Phase III programme and unlocks next chapter in AstraZeneca’s cardiometabolic and kidney portfolio	PU
07/06	CEO of AstraZeneca: “AI is fundamentally changing the way we develop medicines”	AQ
02/06	Multiple Clinical Trial Data for Elecoglipron (AZD5004/ECC5004), an Oral GLP-1 Receptor Agonist, to be Presented at ADA 2026	AQ
02/06	AstraZeneca - Imfinzi plus Imjudo combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolisation-eligible unresectable liver cancer in EMERALD-3 Phase III trial	AQ